Quarterly ResultMay 13, 2026, 04:53 PM
Valneva Q1 Net Loss €32.1M; Cuts 2026 Sales Guidance to €135-150M
AI Summary
Valneva SE reported a significant increase in net loss to €32.1 million in the first quarter of 2026, with total revenues declining to €30.9 million, primarily due to the wind-down of third-party sales and shipment phasing. The company revised its 2026 product sales guidance downwards to €135-150 million, citing adverse trends in travel vaccine uptake. Despite the financial downturn, Valneva reduced its operating cash burn to €0.3 million and launched a restructuring plan to cut operating expenses by 25-35% and workforce by 10-15%. Key pipeline progress includes Pfizer's expected regulatory submissions for the Lyme disease vaccine candidate and the authorization for local manufacturing of the Chikungunya vaccine in Brazil.
Key Highlights
- Total revenues decreased to €30.9 million in Q1 2026 from €49.2 million in Q1 2025.
- Net loss significantly increased to €32.1 million in Q1 2026 from €9.2 million in Q1 2025.
- Operating cash burn improved to €0.3 million in Q1 2026, down from €8.1 million in Q1 2025.
- Cash position was €105.3 million as of March 31, 2026, excluding €37.0 million from an April offering.
- 2026 product sales guidance revised down to €135 million to €150 million from €145 million to €160 million.
- Company initiated a restructuring plan to reduce global workforce by 10-15% and operating expenses by 25-35% in 2026.
- Pfizer is expected to file regulatory submissions for the Lyme disease vaccine candidate (LB6V) following positive Phase 3 results.
- Brazil authorized local manufacturing of Valneva's Chikungunya vaccine (IXCHIQ®) by Instituto Butantan.